The comparability of Anti-Spike SARS-CoV-2 antibody tests is time-dependent: a prospective observational study
Preprint
- 5 September 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
Objectives Various commercial anti-Spike SARS-CoV-2 antibody tests are used for studies and in clinical settings after vaccination. An international standard for SARS-CoV-2 antibodies has been established to achieve comparability of such tests, allowing conversions to BAU/ml. This study aimed to investigate the comparability of antibody tests regarding the timing of blood collection after vaccination. Methods For this prospective observational study, antibody levels of 50 participants with homologous AZD1222 vaccination were evaluated at 3 and 11 weeks after the first dose and 3 weeks after the second dose using two commercial anti-Spike binding antibody assays (Roche and Abbott) and a surrogate neutralization assay. Results The correlation between Roche and Abbott changed significantly depending on the time point studied. Although 3 weeks after the first dose, Abbott provided values three times higher than Roche, 11 weeks after the first dose, the values for Roche were twice as high as for Abbott, and 3 weeks after the second dose even 5-6 times higher. Conclusions The comparability of quantitative anti-Spike SARS-CoV-2 antibody tests is highly dependent on the timing of blood collection after vaccination. Therefore, standardization of the timing of blood collection might be necessary for the comparability of different quantitative SARS-COV-2 antibody assays.Keywords
Other Versions
- Published version: Version Microbiology Spectrum, 10, preprints
This publication has 75 references indexed in Scilit:
- Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 PatientsJournal of Clinical Microbiology, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportThe New England Journal of Medicine, 2020
- Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on SpecificityClinical Chemistry, 2020
- SeroTracker: a global SARS-CoV-2 seroprevalence dashboardThe Lancet Infectious Diseases, 2020
- A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interactionNature Biotechnology, 2020
- Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological studyThe Lancet, 2020
- Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based studyThe Lancet, 2020
- Immunology of COVID-19: Current State of the ScienceImmunity, 2020
- Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervalsEmerging Microbes & Infections, 2020
- Usage Data and Scientific Impact of the Prospectively Established Fluid Bioresources at the Hospital-Based MedUni Wien BiobankBiopreservation and Biobanking, 2018